- Home
- GOSS vs SOPH Comparison
GOSS vs SOPH Comparison
Compare GOSS & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- SOPH
- Stock Information
- Founded
- GOSS 2015
- SOPH 2011
- Country
- GOSS United States
- SOPH Switzerland
- Employees
- GOSS N/A
- SOPH N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GOSS Health Care
- SOPH Health Care
- Exchange
- GOSS Nasdaq
- SOPH Nasdaq
- Market Cap
- GOSS 246.6M
- SOPH 247.0M
- IPO Year
- GOSS 2019
- SOPH 2021
- Fundamental
- Price
- GOSS $1.07
- SOPH $3.14
- Analyst Decision
- GOSS Strong Buy
- SOPH Strong Buy
- Analyst Count
- GOSS 5
- SOPH 3
- Target Price
- GOSS $9.20
- SOPH $7.00
- AVG Volume (30 Days)
- GOSS 969.4K
- SOPH 33.6K
- Earning Date
- GOSS 11-07-2024
- SOPH 11-05-2024
- Dividend Yield
- GOSS N/A
- SOPH N/A
- EPS Growth
- GOSS N/A
- SOPH N/A
- EPS
- GOSS N/A
- SOPH N/A
- Revenue
- GOSS $95,842,000.00
- SOPH $64,938,000.00
- Revenue This Year
- GOSS N/A
- SOPH $7.70
- Revenue Next Year
- GOSS N/A
- SOPH $20.61
- P/E Ratio
- GOSS N/A
- SOPH N/A
- Revenue Growth
- GOSS N/A
- SOPH 20.14
- 52 Week Low
- GOSS $0.45
- SOPH $2.49
- 52 Week High
- GOSS $1.60
- SOPH $7.37
- Technical
- Relative Strength Index (RSI)
- GOSS 62.64
- SOPH 33.65
- Support Level
- GOSS $0.98
- SOPH $3.21
- Resistance Level
- GOSS $1.07
- SOPH $4.10
- Average True Range (ATR)
- GOSS 0.07
- SOPH 0.29
- MACD
- GOSS 0.01
- SOPH -0.08
- Stochastic Oscillator
- GOSS 83.26
- SOPH 8.15
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.